Analyst Ratings for Momenta Pharmaceuticals (MNTA)
MNTA Rating Summary
MNTA Price Target Summary
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$20.38 (+56.4%)
Avg. $ Target:
$20.38 (+56.4%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/19/2013 | BofA/Merrill Lynch | Downgrade | Underperform (Neutral) |
N/A (N/A) |
13.86 | 13.03 | -5.99% | Details |
| 7/20/2012 | UBS » Updated 8/6/2012 |
Downgrade | Neutral (Buy) |
14.00 (15.00) |
14.39 | 13.03 | -9.45% | Details |
| 6/25/2012 | Canaccord Genuity » Updated 8/6/2012 |
Downgrade | Hold (Buy) |
12.00 (12.00) |
13.50 | 13.03 | -3.48% | Details |
| 1/5/2012 | Bernstein | New Coverage | Outperform (N/A) |
24.00 (N/A) |
17.73 | 13.03 | -26.51% | Details |
| 9/20/2011 | Cowen | Downgrade | Neutral (N/A) |
N/A (N/A) |
12.30 | 13.03 | 5.93% | Details |
| 8/5/2011 | Monness, Crespi, Hardt | Upgrade | Buy (N/A) |
25.00 (N/A) |
17.25 | 13.03 | -24.46% | Details |
| 12/20/2010 | Goldman Sachs » Updated 2/10/2012 |
New Coverage | Neutral (N/A) |
16.00 (N/A) |
15.45 | 13.03 | -15.66% | Details |
| 11/20/2009 | Oppenheimer » Updated 8/4/2011 |
New Coverage | Outperform (N/A) |
24.00 (N/A) |
11.29 | 13.03 | 15.41% | Details |
